HPV vaccine after stem cell transplant
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests if the HPV vaccine works safely in people who received a stem cell transplant from a donor. It may help prevent HPV-related cancers in transplant survivors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a stem cell transplant from a related or unrelated donor.
- You are between 18 and 45 years old.
- You do not have very low platelets that would make a shot unsafe.
- You do not have severe graft-versus-host disease (GVHD) that is hard to control.
- You are not pregnant or planning pregnancy during the vaccine period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a CMV vaccine to stem cell donors can help protect recipients from CMV infection after transplant. It is for adults with specific blood cancers who are CMV-positive and have a matched related donor.
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
This trial is for people with high-risk acute lymphoblastic leukemia who are getting a stem cell transplant from a family donor. After transplant, you'd receive a treatment that combines specially designed immune cells (CAR T cells) that target your leukemia, plus a vaccine that helps those cells work better.
Hear when a new HPV (Human Papillomavirus)-Associated trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.